Kiniksa presents Rilonacept final Phase 2 clinical data
Kiniksa Pharmaceuticals reported final data from an open-label Phase 2 clinical trial of rilonacept, a weekly, subcutaneously-injected, recombinant fusion protein that blocks IL-1alpha and IL-1beta signaling. The data were included in a poster presentation at the American Heart Association, or AHA, Scientific Sessions 2019. The Phase 2 data provided first evidence that rilonacept treatment improved clinically meaningful outcomes associated with the unmet medical need in recurrent pericarditis. "The final Phase 2 data showed the potential for rilonacept to improve clinically meaningful outcomes associated with unmet need in recurrent pericarditis," said Sanj Patel, CEO of Kiniksa. "Rilonacept treatment in the Phase 2 trial led to a rapid resolution of recurrent pericarditis episodes that was sustained throughout the 6-month study as well as an improvement in overall quality of life scores. Treatment with rilonacept also led to a decrease in the annualized incidence of pericarditis episodes and importantly supported the discontinuation of corticosteroids without pericarditis recurrence. These data further confirm our confidence in the design of RHAPSODY, our pivotal Phase 3 trial of rilonacept in recurrent pericarditis, for which we expect top-line data in the second half of 2020."